منابع مشابه
High-altitude pulmonary hypertension.
High-altitude pulmonary hypertension (HAPH) is a specific disease affecting populations that live at high elevations. The prevalence of HAPH among those residing at high altitudes needs to be further defined. Whereas reduction in nitric oxide production may be one mechanism for the development of HAPH, the roles of endothelin-1 and prostaglandin I₂ pathways in the pathogenesis of HAPH deserve f...
متن کاملSupplemental L-arginine Modulates Developmental Pulmonary Hypertension in Broiler Chickens Fed Reduced-Protein Diets and Reared at High Altitude
This experiment was conducted to evaluate the effects of supplemental L-arginine (ARG) in reduced-protein diets on cardiopulmonary performance and intestinal morphology in the broilers reared at high altitude. A total of 156 day-old male broilers were randomly assigned to 3 treatments and 4 replicates of 13 chicks and reared up to 42 days of age. Treatment groups were designed as a normal-prote...
متن کاملHigh-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude.
BACKGROUND Pulmonary hypertension has not been described as a predisposing risk factor for high-altitude pulmonary edema (HAPE) in children. Previous studies have shown an association of HAPE with abnormally increased pulmonary vasoreactivity to hypoxia but generally normal pulmonary artery pressure (PAP) after recovery. OBJECTIVE To describe HAPE of relatively rapid onset and its management ...
متن کاملMechanisms and drug therapy of pulmonary hypertension at high altitude.
Pulmonary vasoconstriction represents a physiological adaptive mechanism to high altitude. If exaggerated, however, it is associated with important morbidity and mortality. Recent mechanistic studies using short-term acute high altitude exposure have provided insight into the importance of defective vascular endothelial and respiratory epithelial nitric oxide (NO) synthesis, increased endotheli...
متن کاملPULMONARY HYPERTENSION Phosphodiesterase type 5 and high altitude pulmonary hypertension
Background: This study explored phosphodiesterase type 5 (PDE5) inhibition as a strategy for treating high altitude pulmonary arterial hypertension (HAPH). Methods: 689 subjects (313 men) of mean (SD) age 44 (0.6) years living above 2500 m were screened for HAPH by medical examination and electrocardiography, and 188 (27%) met the criteria for right ventricular hypertrophy. 44 underwent cardiac...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2019
ISSN: 0903-1936,1399-3003
DOI: 10.1183/13993003.00985-2019